Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib for steroid-refractory chronic graft-versus-host disease after allogeneic stem cell transplantation in Chinese patients
CTR20252724Phase 4Active
- Sponsor
- Novartis
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ruxolitinib in graft-versus-host disease (GVHD), sponsored by Novartis. Started Sep 2025; status: active.
02
Drugs
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on CTR20252724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252724.